[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-cystic-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-cystic-fibrosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100374584","pulmonary-condensate-non-invasive-evaluation-of-pulmonary-involvement-in-asthma-and-cystic-fibrosis-100374584",false,"NCT04157361","Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.","Inclusion Criteria:\n\n* Children\u002Fadults with moderate or IgE mediated asthma\n* Children\u002Fadults with cystic fibrosis\n* Healthy control children\u002Fadults without lung disorders\n\nExclusion Criteria:\n\n\\-",true,"ALL",{"count":19,"type":20},450,"ESTIMATED","OBSERVATIONAL","Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung injury, inflammation and infectious complications in chronic diseases like (CF) Cystic fibrosis or (AB) Bronchial asthma would be highly beneficial. Investigators propose to establish EBC \"breathprints\" revealing molecular signatures of pulmonary inflammation and specific respiratory bacterial infections of CF patients and AB. Investigators hypothesize that the analysis of EBC can reveal biomarkers specific for severity of the inflammation, and infection caused by opportunistic pathogens such as P. aeruginosa (PA). With these breath-prints, investigators also propose to establish correlations between respiratory microbiota using traditional methods and CF lung disease severity. Together, the studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of AB and monitoring of CF disease activity, treatment efficacy and PA or another opportunistic infections.",[24,25],"Bronchial Asthma","Pulmonary Cystic Fibrosis",[27,28,29],"Breath condensate","Bronchial asthma","Cystic Fibrosis","RECRUITING","2026-03-19",{"date":33,"type":34},"2026-03-23","ACTUAL",{"date":36,"type":34},"2015-05-01",{"date":38,"type":20},"2026-12-31",{"name":40,"class":41},"The Institute of Molecular and Translational Medicine, Czech Republic","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100416261","characterization-of-antibacterial-antibodies-in-patients-with-cystic-fibrosis-100416261","NCT04700358","Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis","Identification and Characterization of Antibacterial Antibodies in Sera of Patients With Cystic Fibrosis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to give consent\n* Normal vital signs including:\n* Blood pressure systolic value 150 - 100 mmHg, diastolic value \\\u003C 90 mmHg\n* Respiratory rate \\\u003C 20\u002Fmin\n* Oxygen saturation \\>92%\n* Heart rate 50 - 110\u002Fmin\n* Body temperature \\\u003C38°C\n\nExclusion Criteria:\n\n* Cytopenia (leukocytes \\\u003C 1.500\u002Fµl, thrombocytes \\\u003C 50.000\u002Fµl, Hemoglobin \\\u003C 12 g\u002Fdl)\n* Heart disease or pulmonary hypertension\n* Body weight \\\u003C50 kg (exclusion of blood sampling for B cell isolation)\n* Blood donation, larger blood loss and\u002For major surgery in the last 8 (male) or 12 (female) weeks\n* Any decline of the general state of health in the last 3 month including weight loss \\> 2kg, pulmonal exacerbation or increased impairment of pulmonary function (FEV1 \\\u003C 50%)","18 Years",{"count":52,"type":20},75,"Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria such as Pseudomonas aeruginosa or Staphylococcus aureus. Aim of this study is to detect virulence factor neutralizing antibodies in the sera of the study population followed by B cell repertoire analyses to design B cell-derived neutralizing monoclonal antibodies. The functionality of neutralizing antibodies rests on inhibition of virulence factors by binding of crucial epitopes rather than merely the induction of opsonization. Focusing on patients with bacterial colonization\u002Fchronic infections or a history of an acute infection in the past, will increase the likelihood for identification of serum with neutralizing activity as in vivo antigen contact is a prerequisite for antibody development and maturation. Since virulence factors are essential for infection, dissemination and tissue damage, inhibition of these factors by developed neutralizing antibodies might contribute to a favorable outcome of life-threatening infections.",[25,55],"Neutralizing Antibodies","2024-05-07",{"date":58,"type":34},"2024-05-08",{"date":60,"type":34},"2020-10-01",{"date":62,"type":20},"2027-12-31",{"name":64,"class":41},"University Hospital of Cologne"]